Literature DB >> 11563078

1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106)1: antitumor effect and mechanism of action.

A Azuma1, A Matsuda, T Sasaki, M Fukushima.   

Abstract

The antitumor activity, cellular metabolism and mechanism of action of the antitumor nucleoside analog, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd) are described.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11563078     DOI： 10.1081/NCN-100002337

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN： 1525-7770            Impact factor:   1.381


  4 in total

1.  ATP chemosensitivity testing of new antitumor duplex drugs linking 3`-C-ethynylycytidine (ECyd) and 2´-deoxy-5-fluorouridine (5-FdU) in comparison to standard cytostatica and combinations thereof.

Authors:  Sarah Schott; Markus Wallwiener; Beate Kootz; Harald Seeger; Tanja Fehm; Hans Neubauer
Journal:  Invest New Drugs       Date:  2009-12-09       Impact factor: 3.850

Review 2.  The Metabolic and Non-Metabolic Roles of UCK2 in Tumor Progression.

Authors:  Yi Fu; Xin-Dong Wei; Luoting Guo; Kai Wu; Jiamei Le; Yujie Ma; Xiaoni Kong; Ying Tong; Hailong Wu
Journal:  Front Oncol       Date:  2022-05-20       Impact factor: 5.738

3.  A nucleoside anticancer drug, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expression.

Authors:  Shunsuke Meike; Tohru Yamamori; Hironobu Yasui; Masato Eitaki; Akira Matsuda; Masami Morimatsu; Masakazu Fukushima; Yasundo Yamasaki; Osamu Inanami
Journal:  Mol Cancer       Date:  2011-07-28       Impact factor: 27.401

4.  Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer.

Authors:  Anne Tsao; Edwin Pun Hui; Rosalyn Juergens; Shanthi Marur; Tan Eng Huat; Goh Boon Cher; Ruey-Long Hong; Waun Ki Hong; Anthony Tak-Cheung Chan
Journal:  Cancer Med       Date:  2013-04-18       Impact factor: 4.452
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.